Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Monocyte Subpopulations and Their Expression of HLA-DR and CD300e after Allogeneic Stem Cell Transplantation in Patients with or without GvHD

Igor Age Kos, Jörg-Thomas Bittenbring, Onur Cetin, Vadim Lesan, Konstantinos Christofyllakis, Frank Neumann, Lorenz Thurner, Moritz Bewarder

Blood (2023) 142 (Supplement 1): 7010.

https://doi.org/10.1182/blood-2023-185530

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Moritz Bewarder, Michelle Elbert, Konstantinos Christofyllakis, Kristina Heyne, Gabi Carbon, Natalie Fadle, Evi Regitz, Maximilian Kiefer, Igor Age Kos, Joerg Thomas Bittenbring, Frank Neumann, Falko Fend, Irina Bonzheim, Lorenz Thurner

Blood (2022) 140 (Supplement 1): 3042–3043.

https://doi.org/10.1182/blood-2022-170027

Published: 2022

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Blood (2021) 137 (23): 3251–3258.

https://doi.org/10.1182/blood.2020008835

Published: 2021

Includes: Supplemental data

Journal Articles

Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Lorenz Thurner, MD, Viola Poeschel, MD, Bettina Altmann, PhD, Herve Tilly, MD PhD, Marc Andre, MD, Marie Maerevoet, MD, Thomas Weber, MD, Joerg Hoffmann, MD, Martin Dreyling, MD, Herve Maisonneuve, MD, Andrea Kerkhoff, MD, Steven Le Gouill, MD PhD, Stephan Stilgenbauer, MD, Marita Ziepert, PhD, Roch Houot, MDPhD, Corinne Haioun, MDPhD, Gerhard Held, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-139459

Published: 2020

Journal Articles

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Moritz Bewarder, MD, Gerhard Held, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, MD, Arne Felbel, Dominic Kaddu-Mulindwa, MD, Niels Murawski, MD, Stephan Stilgenbauer, Frank Neumann, PhD

Blood (2019) 134 (Supplement_1): 5616.

https://doi.org/10.1182/blood-2019-126998

Published: 2019

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

Hyper- N -glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Blood (2018) 132 (26): 2744–2753.

https://doi.org/10.1182/blood-2018-03-836932

Published: 2018

Includes: Supplemental data

Journal Articles

Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma

Lorenz Thurner, MD, Sylvia Hartmann, MD, Theresa Bock, Natalie Fadle, Maria Kemele, Evi Regitz, Moritz Bewarder, MD, Sigrun Smola, Thorsten Pfuhl, Jana Held, Rainer-Maria Bohle, Laurence de Leval, MD, Rabea Wagener, Reiner Siebert, PhD, Martin-Leo Hansmann, Stephan Stilgenbauer, MD PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD

Blood (2018) 132 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2018-99-114209

Published: 2018

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

Moritz Bewarder, MD, Lorenz Thurner, MD, Frank Neumann, PhD, Natalie Fadle, Evi Regitz, Maria Kemele, Helene Will, Lisa Goerens, Konstantinos Christofyllakis, MD, Dominic Kaddu-Mulindwa, MD, Stephan Stilgenbauer, Maximilian Kiefer, Klaus Dieter Preuss, PhD

Blood (2018) 132 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2018-99-115348

Published: 2018

Journal Articles

B-Cell Receptor Antigens As the Targeting Moiety for Bispecific Constructs - a Novel Treatment Approach for B-Cell Lymphomas

Moritz Bewarder, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Evi Regitz, Natalie Fadle, Michael Pfreundschuh, MD

Blood (2017) 130 (Supplement 1): 111.

https://doi.org/10.1182/blood.V130.Suppl_1.111.111

Published: 2017

Journal Articles

CD3/Bars: A Novel Bispecific Format for the Treatment of B-Cell Lymphomas

Moritz Bewarder, MD, Klaus-Dieter Preuss, PhD, Natalie Fadle, Evi Regitz, Lorenz Thurner, MD, Michael Pfreundschuh, MD, PhD

Blood (2016) 128 (22): 3516.

https://doi.org/10.1182/blood.V128.22.3516.3516

Published: 2016

Journal Articles

LRPAP1 Is a Frequent B-Cell Receptor Antigen in Mantle Cell Lymphoma (MCL)

Lorenz Thurner, MD, Sylvia Hartmann, Klaus-Dieter Preuss, PhD, Natalie Fadle, Maria Kemele, Evi Regitz, Christiane Pott, MD PhD, Rainer-Maria Bohle, Martin-Leo Hansmann, Michael Pfreundschuh, MD

Blood (2015) 126 (23): 2685.

https://doi.org/10.1182/blood.V126.23.2685.2685

Published: 2015

Journal Articles

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD, Lorenz Thurner, MD, Stefan Barth, Prof.Dr., Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, PhD, Thomas Nachreiner, Dr., Klaus-Dieter Preuss, PhD

Blood (2015) 126 (23): 3995.

https://doi.org/10.1182/blood.V126.23.3995.3995

Published: 2015

Journal Articles

Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas

Lorenz Thurner, MD, Maria Kemele, Natalie Fadle, Evi Regitz, Patrick Roth, MD, Michael Weller, Prof., Monika Szczepanowski, Wolfram Klapper, Camelia-Maria Monoranu, MD, Andreas Rosenwald, MD, Rolf Buslei, MD, Rainer Maria Bohle, MD, Yoo-Jin Kim, MD, Klaus-Dieter Preuss, PhD, Michael Pfreundschuh

Blood (2014) 124 (21): 142.

https://doi.org/10.1182/blood.V124.21.142.142

Published: 2014

NARROW

Monocyte Subpopulations and Their Expression of HLA-DR and CD300e after Allogeneic Stem Cell Transplantation in Patients with or without GvHD

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Hyper- N -glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

B-Cell Receptor Antigens As the Targeting Moiety for Bispecific Constructs - a Novel Treatment Approach for B-Cell Lymphomas

CD3/Bars: A Novel Bispecific Format for the Treatment of B-Cell Lymphomas

LRPAP1 Is a Frequent B-Cell Receptor Antigen in Mantle Cell Lymphoma (MCL)

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only